BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils.

ABSTRACT:

Background

Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)-cross-linked basophils.

Methods

We examined the effects of four BTK inhibitors (ibrutinib, dasatinib, AVL-292, and CNX-774) on IgE-dependent activation and histamine release in blood basophils obtained from allergic patients (n=11) and nonallergic donors (n=5). In addition, we examined the effects of these drugs on the growth of the human basophil cell line KU812 and the human mast cell line HMC-1.

Results

All four BTK blockers were found to inhibit anti-IgE-induced histamine release from basophils in nonallergic subjects and allergen-induced histamine liberation from basophils in allergic donors. Drug effects on allergen-induced histamine releas

SUBMITTER: Smiljkovic D 

PROVIDER: S-EPMC5655929 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature